Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4614 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 21 22 23 ... 45 46 47  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Recursion Pharmaceuticals–Bayer: investment, 202009 financing round Series D totalling $239m incl $50m from new + lead investor Leaps by Bayer 2020-09-09
Recursion Pharmaceuticals–SEVERAL: investment, 202009 financing round Series D $239m led by Leaps by Bayer 2020-09-09
United States (govt)–Valneva: Japanese encephalitis vaccine, 202009–202308 supply $61m + option for up to $105m of Ixiaro to US DoD 2020-09-09
Imcyse–MC Services: public relations, 202009 service existent by MC Services 2020-09-07
Boehringer–BiomX: biomarker discovery, 202009– collab discovery of microbiome-based biomarkers for IBD using XMarker platform 2020-09-02
Evotec–Univ Oxford: biobanking, 202009– collab €na granting Evotec access to QUOD biobank for multi-omics analyses for drug discovery 2020-09-02
BioVersys–SEVERAL: investment, 202009 financing round Series B CHF19m 2020-09-01
Helmholtz–Bruker: NMR spectrometer, 202009c supply 1.2 GHz NMR spectrometer with 28 Tesla to FZ Jülich 2020-09-01
Lobsor–Stada: investment, 202009 acquisition of Lobsor Pharmaceuticals AB by Stada/Britannia 2020-09-01
Switzerland (govt)–Moderna: mRNA-based vaccines, 202009c– contract for supply of 4.5m doses of Covid-19 vaccine candidate mRNA-1273 2020-09-01
Aimmune Therapeutics–Nestlé: investment, 202008– cash tender offer for all remaining shares at $34.5/share representing total equity value of $2.6b 2020-08-31
Semalytix–btov Partners: investment, 202008 financing round Series A totalling €4.3m incl co-lead investor btov 2020-08-31
Semalytix–Fly Ventures: investment, 202008 financing round Series A totalling €4.3m incl existing sedd + co-lead investor Fly Ventures 2020-08-31
Semalytix–SEVERAL: investment, 202008 financing round Series A €4.3m co-led by btov + Fly Ventures 2020-08-31
Aignostics–Berlin (govt): investment, 202008 seed financing round totalling €5m incl co-investor VC Fonds Technologie der IBB 2020-08-28
Aignostics–Boehringer: investment, 202008 seed financing round totalling €5m incl lead investor BIVF 2020-08-28
Aignostics–Hessen (govt): investment, 202008 seed financing round totalling €5m incl co-investor Future Capital 2020-08-28
Aignostics–High-Tech Gründerfonds: investment, 202008 seed financing round totalling €5m incl co-investor HTGF 2020-08-28
Aignostics–SEVERAL: investment, 202008 seed financing round €5m led by BIVF + incl HTGF + IBB VC Fonds Technologie + Future Capital 2020-08-28
Triumvira Immunologics–Bayer: investment, 202008 financing round Series A totalling $55m incl new + co-lead investor Leaps by Bayer 2020-08-27
Triumvira Immunologics–SEVERAL: investment, 202008 financing round Series A $55m co-led by Leaps by Bayer + Northpond Ventures 2020-08-27
Freenome–SEVERAL: investment, 202008 financing round Series C $270m co-led by Bain Capital Life Sciences + Perceptive Advisors 2020-08-26
Univ Guelph–Bruker: NMR spectrometer, 202008 supply existent of 400 MHz NMR spectrometer + Fourier 80 benchtop NRM system 2020-08-24
Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares 2020-08-19
CureVac–Hopp Group: investment, 202008 private placement €100m at $16/share to DH-LT-Investments GmbH + affiliates 2020-08-18
Bayer–Hua Medicine: dorzagliatin, 202008– commercialisation agreement + strategic partnership in China 2020-08-17
Seres Therapeutics–Nestlé: investment, 202008 registered direct offering $20.62m with 959k common stock at $21.5/share to Société des Produits Nestlé 2020-08-17
Seres Therapeutics–SEVERAL: investment, 202008 public offering $225.75m+$33.86m with 10.5m+1.575m shares common stock at $21.5/share 2020-08-17
F2G Ltd–Advent Life Sciences: investment, 202008 financing round totalling $60.8m incl exisiting investor Advent Life Sciences 2020-08-12
F2G Ltd–Cowen: investment, 202008 financing round totalling $60.8m incl new investor Cowen Healthcare Investments 2020-08-12
F2G Ltd–EMS (BR): investment, 202008 financing round totalling $60.8m incl exisiting investor Brace Pharma Capital 2020-08-12
F2G Ltd–Morningside: investment, 202008 financing round totalling $60.8m incl exisiting investor Morningside Ventures 2020-08-12
F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures 2020-08-12
F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors 2020-08-12
Atriva Therapeutics–High-Tech Gründerfonds: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor HTGF 2020-08-11
Atriva Therapeutics–Meneldor: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor Meneldor BV 2020-08-11
Atriva Therapeutics–SEVERAL: credit, 202008– convertible loan financing round €8.6m led by existing investors Meneldor + HTGF 2020-08-11
Bayer–Atomwise: AI-based drug discovery, 202008 collab existent 2020-08-11
Bayer–Linklaters: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
Bayer–Morgan Stanley: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
Kandy Therapeutics–Bayer: investment, 202008–202009 acquisition $425m upfront + $450m developm milestones + triple digit $m sales milestones 2020-08-11
Kandy Therapeutics–Goldman Sachs: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Tx by Bayer 2020-08-11
Kandy Therapeutics–Goodwin Procter: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market 2020-08-10
Immunic–SEVERAL: investment, 202008 underwritten public offering $90m+$13.5m with 5m+750k shares common stock at $18/share 2020-08-10
Bruker–Univ Utrecht: mass spectromtery, 202008– collab developm of methods using crosslinkg MS for proteomics with Heck lab 2020-08-07
T-Knife–Andera Partners: investment, 202008 financing round Series A totalling €66m incl existing + co-investor Andera Partners 2020-08-06
T-Knife–Boehringer: investment, 202008 financing round Series A totalling €66m incl existing + co-investor BIVF 2020-08-06
T-Knife–RA Capital: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor RA Capital Management 2020-08-06
T-Knife–SEVERAL: investment, 202008 financing round Series A €66m co-led by Versant Ventures + RA Capital 2020-08-06
T-Knife–Versant Ventures: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor Versant Ventures 2020-08-06
GentiBio–Novartis: investment, 202008 seed financing round totalling $20m inbcl co-lead investor Novartis Venture Fund 2020-08-05
GentiBio–SEVERAL: investment, 202008 seed financing round $20m led by OrbiMed + Novartis Venture + RA Capital Management 2020-08-05
Matterhorn Biosciences–Versant Ventures: investment, 202008– seed financing $30m commitment from Versant Ventures 2020-08-05
NBE Therapeutics–Optimum Strategic Communications: public relations, 202008 service existent by Optimum 2020-08-03
Varian Medical Systems–Siemens: investment, 202008– acquisition $16.4b in cash of Varian Medical Systems Inc by Siemens Healthineers AG ANNOUNCED 2020-08-02
ArchiMed–SEVERAL: investment, 202008 closing of MED Platform I Fund at €1b 2020-08-01
Electrochaea–EU (govt): grant, 202008 Horizon 2020 EIC Accelerator grant €2.5m 2020-08-01
DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital 2020-07-29
Boehringer–Biognosys: HRM mass spectrometry, 202007– collab using HRM/DIA MS + Spectronaut s/w for drug discovery 2020-07-23
T3 Pharmaceuticals–Boehringer: investment, 202007 3rd financing round totalling CHF25m incl existing investor BIVF 2020-07-22
T3 Pharmaceuticals–OTHER: investment, 202007 3rd financing round totalling CHF25m incl existing private Swiss investors 2020-07-22
T3 Pharmaceuticals–Reference Capital: investment, 202007 3rd financing round totalling CHF25m incl existing investor Reference Capital SA 2020-07-22
T3 Pharmaceuticals–SEVERAL: investment, 202007 3rd financing round CHF25m from existing investors 2020-07-22
T3 Pharmaceuticals–Wille Finance: investment, 202007 3rd financing round totalling CHF25m incl existing investor Wille Finance AG 2020-07-22
Vesigen Therapeutics–Bayer: investment, 202007 financing round Series A totalling $28.5m incl co-lead investor Leaps by Bayer 2020-07-22
Vesigen Therapeutics–SEVERAL: investment, 202007 financing round Series A $28.5m co-led by Leaps by Bayer + Morningside Ventures 2020-07-22
Gain Therapeutics–SEVERAL: investment, 202007 financing round Series B $10m from institutional + accredited investors 2020-07-21
Quantro Therapeutics–Boehringer: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes 2020-07-21
Quantro Therapeutics–Evotec: drug discovery services, 202007– supply of hit identification services by Evotec 2020-07-21
Quantro Therapeutics–Evotec: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes 2020-07-21
Quantro Therapeutics–MC Services: public relations, 202007 service existent by MC Services 2020-07-21
Quantro Therapeutics–SEVERAL: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes 2020-07-21
Tubulis–Bavaria (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Bayern Kapital 2020-07-21
Tubulis–BioMedPartners: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor BioMedPartners 2020-07-21
Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners 2020-07-21
Tubulis–Germany (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Coparion 2020-07-21
Tubulis–High-Tech Gründerfonds: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor HTGF 2020-07-21
Tubulis–Occident: investment, 202007 financing round Series A totalling €10.7m incl co-investor Occident Group 2020-07-21
Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF 2020-07-21
Tubulis–Trophic Communications: public relations, 202007 service existent by Trophic Communications 2020-07-21
Intellia Therapeutics–Cellex: allogeneic cell therapies, 202007– collab RnD genome editing + RevCAR technology for cancer + inflammation Gemoab 2020-07-20
CureVac–Germany (govt): investment, 202007 financing round Series B totalling €560m incl €300m from KfW approx 19% shareholding 2020-07-17
CureVac–GSK: investment, 202007 financing round Series B totalling €560m incl €150m from Glaxo Group Ltd 2020-07-17
CureVac–Qatar (govt): investment, 202007 financing round Series B totalling €560m incl €60m from Qatar Investment Authority 2020-07-17
CureVac–SEVERAL: investment, 202007 financing round Series B €560m incl €300m from KfW + €150m from GSK + €60m from QIA 2020-07-17
TeleClinic–Zur Rose Group: investment, 202007– acquisition of TeleClinic GmbH for mid-double-digit million EUR price by Zur Rose Group 2020-07-16
Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina 2020-07-14
Anergis–Virometix: allergy immunotherapy, 202007– collab research study at HZI using SVLPs supported by TRANSVAC2 grant in house dust mite allergy 2020-07-09
CirQuest Labs–MLM Medical Labs: investment, 202007 acquisition of CirQuest Labs by MLM Medical Labs 2020-07-08
Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications 2020-07-08
Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties 2020-07-08
Molecular Partners–BVF Partners: investment, 202007 private placement totalling CHF80.2m with 5.53m new shares at CHF14.5/share 2020-07-06
Molecular Partners–Camber Capital Management: investment, 202007 private placement totalling CHF80.2m incl investor Camber Capital 2020-07-06
Molecular Partners–Federated Hermes Kaufmann Funds: investment, 202007 private placement totalling CHF80.2m incl investor FHKF 2020-07-06
Molecular Partners–Monashee Investment Management: investment, 202007 private placement totalling CHF80.2m incl investor Monashee 2020-07-06
Molecular Partners–SEVERAL: investment, 202007 private placement CHF80.2m from new + existing European + US institutional investors 2020-07-06
Molecular Partners–Suvretta Capital: investment, 202007 private placement totalling CHF80.2m incl investor Suvretta Capital Management 2020-07-06
Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund 2020-07-03
Bright Peak Therapeutics–SEVERAL: investment, 202007 financing round Series A $35m 2020-07-01
next pagenext page 1 2 3 ... 21 22 23 ... 45 46 47  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top